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Abstract
The PAX2 gene encodes a transcription factor expressed during development. In humans, PAX2 mutations cause
the renal-coloboma syndrome, whereas homozygous mutations are lethal, causing severe organ malformation,
notably in the brain and kidney. Wilms tumor (WT) of the kidney results from a failure in the mesenchymal-epithelial
transition, a crucial step partly controlled by PAX2. Downstream target genes regulated by PAX2 are still undefined.
We therefore hypothesized that identification and characterization of the genes regulated by PAX2 may improve
our understanding of developmentally related malignancies including WT. We used nickel agarose chromatin en-
richment, chromatin immunoprecipitation, and the human embryonic kidney–derived cell line HEK293 to identify
regulatory elements responding to PAX2. Among others, we identified WNT5A as a gene potentially regulated by
PAX2. Here, we demonstrate thatWNT5A is a direct target of PAX2 in HEK293 cells, using both transactivation and
electrophoretic mobility shift assays. We were unable to find any WNT5A disease-associated mutations after
screening a panel of 99 WT samples. However, quantitative reverse transcription–polymerase chain reaction in
human favorable-histology WT revealed that ∼66% of the cases expressed significantly less WNT5A than human
fetal kidney. Moreover, the WiT9 WT cell line revealed a weak expression of the WNT5A gene. A correlation of
decreased WNT5A expression with predominant blastemal histology tumors suggests a possible inhibitory role
in WT pathogenesis. This study underlines the importance of PAX2 in the regulation of WNT5A. Further in vivo
study is necessary to determine whether the PAX2 and WNT5A are truly involved in WT pathogenesis.
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Introduction
Wilms tumor (WT) is the most common renal cancer affecting
young children. The origin of this tumor is in the pluripotent em-
bryonic kidney precursor cells that fail to differentiate properly dur-
ing early renal development [1,2]. Pediatric kidney tumors arise in
the early stem cells of the kidney and are generally responsive to che-
motherapy. In contrast, cancers affecting adult kidney arise from the
tubular cells and are usually highly resistant to therapy.
The association of WT with persistent foci of embryonic tissue
called nephrogenic rests reflects the link with early kidney develop-
ment [2]. Nephrogenic rests consist mainly of blastemal cells with
varying degrees of differentiation. Interestingly, these lesions share
some genetic alterations with their adjacent tumors and suspected
to be precursor lesions to WT [3,4]. It is likely that genes involved
in early kidney development are also involved in the initiation and
progression of WT [5]. Thus, it is important to elucidate the entity
and nature of the genes and mechanisms governing the differentia-
tion of embryonic kidney stem cells.
Two transcription factors PAX2 and WT1 are among such genes
[6–9]. PAX2 belongs to the paired box gene family, characterized by a
conserved domain, the paired box that binds specifically to DNA-
binding sites to initiate regulation [10]. The functions attributed to
PAX2 in different developmental stages, including activation and/or
repression of downstream genes in different cell lineages, are complex
and not completely understood. In developing mammalian kidney,
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PAX2 is one of the earliest markers expressed within the nephric duct
and seems to orchestrate the branching of the ureteric bud through
activation of glial cell line–derived neurotrophic factor (GDNF) and
its corresponding receptor [11,12]. In mice, Pax2 null mutations
cause abnormal kidney development with a marked absence of ure-
teric bud outgrowth [13,14]. Moreover, pax2 plays a crucial role in
the mesenchyme surrounding the ureteric bud and during the early
stage of epithelial differentiation [15–17]. During the apoptotic sup-
pression process, PAX2 seems to play an important role, particularly
during the fixation of nephron number and branching morphogen-
esis [18–21]. Mice hemizygous for Pax2 have reduced numbers of
nephrons, less developed branching, and increased apoptosis in ure-
teric bud cells [19,22]. Delivery of Bax, a proapoptotic gene, to de-
veloping ureteric buds also reduces branching [23]. Conversely,
blocking the expression of the antiapoptotic gene bcl2 or caspases re-
verses the branching defects observed in mice heterozygous for the
pax2 gene [24]. At early stages of kidney development, the branching
ureteric buds signal the neighboring metanephric mesenchymal cells,
inducing them to aggregate and express Pax2 while simultaneously
undergoing profound changes leading to the transition from mesen-
chyme to epithelium. It is believed that Pax2 expression regulates the
mesenchymal-epithelial transition; however, its precise role and the
downstream target genes controlled by Pax2 are not yet known
[13]. To search for evidence that PAX2 has a direct role in WT path-
ogenesis, we previously used denaturing high-performance liquid
chromatography (DHPLC) and sequencing analysis to screen the en-
tire PAX2 coding sequence for mutations. We found no evidence for
disease-causing mutations, suggesting that the direct involvement of
PAX2 in WT is uncommon [25]. However, these data do not exclude
the possibility that the pathway downstream from PAX2 may be in-
volved. Therefore, we used the nickel agarose chromatin enrichment
(NACE) and chromatin immunoprecipitation (ChIP) techniques to
identify genes regulated by PAX2 [26].
In this study, we describe a possible functional role for the PAX2
target gene,WNT5A. We have validatedWNT5A as a PAX2 target by
using electrophoretic mobility shift assay (EMSA) and by polymerase
chain reaction (PCR)–amplifying an enriched chromatin generated
by means of ChIP technique, where an anti-Pax2 polyclonal anti-
body was used. We have also demonstrated that WNT5A is under-
expressed in many favorable-histology WTs relative to fetal kidney.
These data suggest a pathway where the PAX2 gene regulates renal
nephron development through WNT signaling pathway with the
participation of WNT5A gene.
Materials and Methods
Cell Culture
Human fetal kidney cell line HEK293 was purchased from the
American Type Culture Collection (Manassas, VA) and was propa-
gated in minimum essential medium supplemented with 10% fetal
bovine serum and 1% glutamine. The WT cell line WiT49, obtained
recently as a kind gift from Dr. Herman Yeger (Hospital for Sick
Children, Toronto, Ontario, Canada), was propagated in Dulbecco’s
modified Eagle’s medium, containing 15% fetal bovine serum and
1% insulin. Cells were incubated at 37°C in a humidified atmo-
sphere containing 5% CO2, and their growth was monitored until
reaching 60% to 70% confluence, at which stage the medium was
changed and cells were transfected.
Transfection
HEK293 cells were transiently transfected with 4 μg of pcDNA-4/
His/Max-PAX2 DNA vector using the transfection reagent Effectine
(Qiagen Inc., Valencia, CA). HEK293 cells were also transfected with
an empty vector (pcDNA-4/His/Max) as a negative control. After
24 and 36 hours of incubation at 37°C in a humidified incubator con-
taining 5% CO2, cells were subjected to NACE or ChIP [26].
Polymerase Chain Reaction Amplification
All primers used for the PCR amplification were designed using
the PRIMER3 software package (http://frodo.wi.mit.edu/cgi-bin/
primer3/primer3_www.cgi) and their sequences are listed in Table 1.
Amplification products were resolved on 1% agarose gel stained with
ethidium bromide.
Nickel Agarose Chromatin Enrichment and ChIP
Both NACE and ChIP analyses were performed as described ear-
lier, with slight changes in sonication time and washing stringency
[26,27]. For NACE assays, HEK293 cells were fixed in their culture
medium and lysed to extract and sonicate DNA five times for 20 sec-
onds each to obtain sizes ranging between 200 and 1000 bp. Purified
chromatin was then incubated with Ni2+ agarose beads for 6 hours
and washed, and DNA/protein complexes were purified as described
earlier [26]. After reversing the cross-linking of the complexes formed
by DNA/proteins, DNA was purified through Qiagen columns after
a complete digestion of proteins. We recently succeeded to optimize
conditions for a specific anti-Pax2 antibody used in ChIP that was
carried out exactly as described above for NACE with the exception
of replacing Ni2+ with a polyclonal Pax2 antibody and a final puri-
fication through phenol chloroform extraction [26,28]. A mouse IgG
polyclonal antibody was used as a negative control for ChIP assays.
Cloning and Sequencing of the NACE-Enriched Chromatin
Five hundred nanograms of the enriched DNAwas end-filled and li-
gated to the EcoRV-digested pBluescript II SK(−) vector (Stratagene,
La Jolla, CA). Ligation products were used to transform XL-Blue com-
petent cells, and DNA from putative-positive clones was extracted.
Enzymatic digestions confirmed the presence of the insert, and positive
clones were sequenced on an automated sequencer (CEQ8000 Ge-
netic Analysis System; BeckmanCoulter,Mississauga, Ontario, Canada)
using dye terminator cycle sequencing chemistry (Beckman Coulter).
Construct Preparation
The PAX2 cDNA encoding the entire open reading frame was
subcloned into EcoRI-XbaI sites in the pcDNA4-His/Max plasmid
Table 1. Sequence of Primers Used for PCR Assays.
Forward Reverse
5′-GAG GAG AAG CGC AGT CAA TC-3′ 5′-GAA GAG GAA GAA CAC GCA CA-3′
5′-CCA CCT CGA GAT TTC ACG TA-3′ 5′-TTT TCC TAC CTA TCT GCA TCA CC-3′
5′-GCC AGT GAT CCC TTG TCC T-3′ 5′-GGG CAA GGT GAG AAG ACA GA-3′
5′-CAT CTG GCT CCT CCA TGA AT-3′ 5′-GGT GGC ACC CAC TAC TTG-3′
5′-ATG AGT CCA ACA TGC AGA GA-3′ 5′-GTA ACT GTA TCA GTG AAA AT-3′
5′-ATG AGT CCA ACA TGC AGA GA-3′ 5′-GTT GGC AGG CAC AGC TGG TT-3′
5′-AAC CAG CTG TGC CTG CCA AC-3′ 5′-GTA ACT GTA TCA GTG AAA AT-3′
The PCR conditions were optimized to amplify a specific band of expected size using DNA sam-
ples as templates. The NACE-enrichedWNT5A 5′-upstream element (AB) was amplified totally or
partially (subfragments A and B) before cloning.
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(Invitrogen, Carlsbad, CA). The WNT5A 5′-upstream enriched frag-
ment (AB) of ∼300 bp was amplified and cloned first into pGEM-T-
easy vector (Promega, Madison, WI) and subsequently subcloned
upstream of the luciferase gene in the pGL3 vector (Promega).
The AB fragment was subdivided by PCR amplification into units,
A and B, of ∼155 and ∼145 bp, respectively. The fragments were
subcloned upstream to the luciferase reporter in pGL3 vector as de-
scribed above. A synthesized fragment (P2BS1) of 54 bp, containing
a confirmed PAX2 binding site [29], was end-filled, cloned upstream
to the cytomegalovirus promoter of the pGL3 vector, and used as a
positive control for transactivation.
Transactivation Assays
We amplified fragment AB covering the total ∼300 bp as well as
overlapping fragments A and B, which, together, covered the total
region of ∼300 bp. The three amplicons A, B, and AB were each
cloned into a TA vector-sequenced and subcloned into pGL3-CMV-
luciferase reporter vector. HEK293 cells were cultured in 12-well
plates at a density of 1 × 105 cells/ml and cotransfected 36 hours
later with PAX2-pcDNA4-His/Max or pcDNA4-His/Max and 300 ng
of pGL3 vector containing either the PAX2 binding site or frag-
ments A, B, and AB placed upstream of the Luciferase gene in
pGL3. Twenty-four hours later, cells were harvested and subjected
to luciferase activity–monitoring according to the manufacturer’s
guidelines (Promega). A reporter construct containing one PAX2
binding site [29] (P2BS-pGL3, see sequence in Table 2) was used
as positive control. For each set of experiments, transfections were
performed in triplicates and repeated three times for confirmation.
Electrophoretic Mobility Shift Assays
In addition to the P2BS oligonucleotides containing the PAX2
binding site, six overlapping oligonucleotides (α, β, γ, δ, ɛ, and ζ)
covering the total sequence of the A fragment were synthesized
(Table 2) with one strand conjugated to biotin. HEK293 cells express-
ing endogenous and recombinant PAX2 proteins were lysed, and
protein extracts were resolved on 6% polyacrylamide Tris-glycine-
EDTA. Five micrograms of protein extracts was incubated with
1.3 mM DTT, 5 μg of sheared salmon sperm DNA, 1 μg of poly
dIdC (Sigma, St. Louis, MO), and biotin-labeled oligonucleotides
(α, β, γ, δ, ɛ, and ζ) as well as P2BS fragments. Samples were incu-
bated at room temperature for 20 minutes to form protein-DNA com-
plexes. After 45 minutes of a prerun of the gel, samples were analyzed
by electrophoresis. Protein-DNA complexes were subsequently trans-
ferred to a membrane, and signals were revealed by using a chemilu-
minescent nucleic acid detection module (Pierce, Rockford, IL).
Supershift Assay
Ten micrograms of HEK293 protein extract was incubated over-
night with 2 μg of anti-Pax2 antibody (Santa Cruz Biotechnology,
Santa Cruz, CA) in 12 μl of 5% skim milk. Biotin-labeled probes
were subsequently added and incubated for another 20 minutes at
room temperature. Samples were resolved on a 5% acrylamide gel
using 1× TGE buffer (50 mM Tris, 380 mM glycine, and 2 mM
EDTA, pH 8.2) at 4°C for 1.5 hour using 20 mA. The transfer
and the detection of the signal were performed as above for EMSA.
Silencing of PAX2 and WNT5A
Two oligonucleotides designed for each of the two genes PAX2
and WNT5A to specifically knock down their expression, were pur-
chased from Qiagen and their sequences are as follow: PAX2-
siRNA1 5′-CACAGCTACACGCCCATTAAA-3′; PAX2-siRNA2
5′-CCCGTAGTTGCTCTTTCGGTA-3′; WNT5A-siRNA2 5′-
CCGGATAACCTTGTAACATAT-3′; WNT5A-siRNA6 5′-TTGG-
TGGTCGCTAGGTATGAA-3′. siRNA duplexes were transfected
into WiT49 cells using HiPerFect (Qiagen) according to the manu-
facturer’s instructions. Cells were plated into 60 mm and/or six-well
dishes at a density of 5 × 104 cells/ml 24 hours before transfections.
A total of 5 μl of 20 μM siRNA solution and 20 μl of the trans-
fection reagent HiPerFect (Qiagen) were incubated with 0.5 ml of
serum-free Dulbecco’s modified Eagle’s medium for 10 minutes be-
fore adding the resulting mixture to the cells dropwise. For data con-
firmation, each siRNA transfection was processed in duplicate.
Protein Extraction and Western Blot
Twenty-four hours of incubation after transfection, cells were
rinsed twice with cold phosphate-buffered saline and lysed in protein
lysis buffer (20 mM N -2-hydroxyethylpiperazine-N ′-2-ethanesulfonic
acid pH 7.6, 75 mM NaCl, 2.5 mM MgCl2, 0.1 mM ethylenedi-
aminetetraacetic acid, 0.1% Triton X-100, 1 μg/ml leupeptin, 1 μg/ml
aprotinin, 1 μg/ml pepstatin, and 1 mM phenylmethylsulfonyl fluo-
ride). The cell lysates were kept on ice for 10 minutes, rotated at 4°C
for 20minutes, and centrifuged at 10,000 rpm for 15minutes, and the
supernatant was subjected to Bradford protein assay using a BioRad
kit (Bio-Rad, Hercules, CA) to determine protein concentrations
using bovine serum albumin as a standard control. Equal amounts
of proteins from each set of experiments were loaded on a 6% acryl/
bisacrylamide gel. BecauseWNT5A is a secreted protein, its detection
required the collection of the medium at 24 hours of incubation after
transfection, then concentration through a “centricon” concentrator
column and quantification.
Table 2. Sequence of Oligonucleotides Used for EMSA.
Oligos Sense—Biotin-Labeled Antisense
P2BS 5′-TTC GTG GTC ATG TAA GTT GTT TCA CTT GGA TGA
AAT CCC TCT TCA GGA GAT GTT-3′
5′-AAC ATC TCC TGA AGA GGG ATT TCA TCC AAGTGA
AAC AAC TTA CAT GAC CAC GAA-3′
α 5′-ATG AGT CCA ACA TGC AGA GAG AAG CAG AGA-3′ 5′-TCT CTG CTT CTC TCT GCA TGT TGG ACT CAT-3′
β 5′-GAA GCA GAG AAG AGA GAT GAA TGC AAC AGG-3′ 5′-CCT GTT GCA TTC ATC TCT CTT CTC TGC TTC-3′
γ 5′-ATG CAA CAG GGG TGG GAG AGA TGG AAA GAT-3′ 5′-ATC TTT CCA TCT CTC CCA CCC CTG TTG CAT-3′
δ 5′-ATG GAA AGA TAG AGA GAT AGA CAG AGA CAG-3′ 5′-CTG TCT CTG TCT ATC TCT CTA TCT TTC CAT-3′
ɛ 5′-ACA GAG ACA GAG GCA GAG AGA TCT GAG AAC-3′ 5′-GTT CTC AGA TCT CTC TGC CTC TGT CTC TGT-3′
ζ 5′-ATC TGA GAA CCA GCT GTG CCT GCC AAC-3′ 5′-GTT GGC AGG CAC AGC TGG TTC TCA GAT-3′
γ′ 5′-TAC GTT GTC CCC ACC CTC TCT ACC TTT CTA-3′ ATG CAA CAG GGG TGG GAG AGA TGG AAA GAT-3′
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The protein extracted from WiT49 cells or concentrated me-
dium were resolved on 10% polyacrylamide gel and transferred to
a nitrocellulose membrane. Immunoblot analyses for Pax2 and Wnt5a
proteins were performed with rabbit polyclonal and monoclonal anti-
bodies respectively (cell signaling, dilution of 1:150). Immunoblots
were incubated overnight at 4°C and followed by 2 hours of incuba-
tion at room temperature with an HRP-conjugated antirabbit IgG sec-
ondary antibody (dilution 1:5000; Cell Signaling, Danvers, MA).
Generated signals were revealed by chemiluminescent protein detec-
tion kit (Pierce).
In Silico Analysis
Both Ensembl (http://www.ensembl.org/index.html) and National
Center for Biotechnology Information (NCBI; http://www.ncbi.nlm.
nih.gov/) Web sites were used for the BLAST analysis of the relevant
clones, for the screening of the nucleotide databases for other species,
and for the localization of regions similar to the WNT5A upstream
element [30]. Similar sequences from human and mouse were aligned
using the NCBI Web site.
Mutation Analysis
DNA preparation and mutational analysis were performed as de-
scribed earlier [25]. DNA samples from 99 favorable-histology WT
cases were obtained from the Renal Tumors Bank of the Children’s
Oncology Group [31] after approval from our institutional research
ethics committee. Exons 1 to 4 of the human WNT5A were subjected
to PCR amplification using the panel of primers listed in Table 1. For
each WT sample, a wild type DNA control was amplified in parallel
under the same conditions. The specificity of the PCR products was
monitored by electrophoresis on a 1.5% agarose gel.
For DHPLC analysis, 10 μl of PCR product from eachWTand from
the wild type were mixed together, heated to 95°C for 5 minutes, and
cooled to 25°C at a rate of 1.5°C/min. Denaturing high-performance
liquid chromatography analysis was performed using the WAVE nu-
cleic acid fragment system (Transgenomics, Omaha, NE) equipped
with a L7300+ column oven using a DNA Sep column as described ear-
lier [25].
Quantitative Reverse Transcription–Polymerase Chain
Reaction and Statistical Analysis
Thirty-eight frozen tissue samples of favorable-histology WTwere
subjected to total RNA extraction using TRIzol reagent (Life Tech-
nologies, Gaithersburg, MD). After DNase treatment, 5 μg of each
RNA sample was run on a denaturing agarose gel, and the quality of
RNA was monitored under UV light using ethidium bromide stain-
ing of the gel. cDNA was produced using 0.5 μg of RNA with the
SuperScript II Reverse Transcriptase (Invitrogen). Quantitative PCRs
were carried out using the 7900HT Fast Real-Time PCR systems
(Applied Biosystems, Foster City, CA) and performed following the
guidelines provided by the company (Applied Biosystems) using the
TaqMan Gene Expression Assay Kit. All cDNA samples were assayed
in triplicate for each primer set. Primers to amplify ∼140-bp fragments
of WNT5A and GAPDH genes together with specific probe for each
gene were included in the 20× TaqMan Gene Expression Assay Mix
(Applied Biosystems). Expression data normalized to GAPDH and
fetal kidney controls were analyzed using the ΔΔC t method [32].
The Children’s Oncology Group Renal Tumors Reference Pathologist
categorized tumor histology.
Results
Nickel Agarose Chromatin Enrichment Generates Potential
Candidate Genes Regulated by PAX2
At the start of this project, we were unable to find a highly specific
Pax2 antibody as required in ChIP analysis. Thus, we used the NACE
technique, an antibody-free affinity-enrichment method based on
Ni2+-NTA affinity chromatography, a variant of ChIP that can be
used as an alternative to overcome the lack of a specific antibody
and nonspecific cross-linking [26]. We have used the human embry-
onic kidney cell line HEK293 as a model system to identify gene
targets of PAX2 and its regulation of gene expression. Pax2 protein
expression was detectable by Western blot in HEK293 cells (Fig-
ure 1A), making it an appropriate model to isolate and test the pre-
dicted PAX2-target regulatory elements.
DNA fragments from 140 PAX2 NACE clones were sequenced
and BLAST-searched in public sites at NCBI (http://www.ncbi.
nlm.nih.gov/) and Ensembl (http://www.ensembl.org/index.html).
BLAST analysis revealed DNA sequences related to 1 adhesion mole-
cule, 23 novel genes, 5 proto-oncogenes, and 11 transcription factors
includingWNT5A,WT1,WIT1, and the SOX11 genes. The remain-
ing 76 clones were repetitive sequences or could not be sequenced and
were excluded from further investigations. Table 3 lists the NACE-
generated putative regulatory elements binding to PAX2. Whereas
the identification of genes such as WT1, previously described as a
PAX2-target gene supports the specificity of the NACE procedure,
validation experiments were, nevertheless, undertaken for candidate
Figure 1. Endogenous PAX2 binds to WNT5A 5′-upstream region.
(A) Western analysis of Pax2 protein expression in HEK293 cells
nuclear extract. (B) Chromatin immunoprecipitation was per-
formed using a polyclonal antibody directed against Pax2. The en-
riched chromatin was amplified using primers flanking the NACE
enriched WNT5A 5′-upstream region. A specific band of an ex-
pected size (∼300 bp) was obtained in the sample treated with
the anti-Pax2 antibody but not in samples treated with an anti-IgG
or mock controls.
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genes, which we intended to characterize (Figure 2). Owing to the
known central role of the WNT pathway in the development of the
kidney, we chose to further analyze the WNT5A gene first.
Confirmation of WNT5A As a Target Regulated by PAX2
To determine whether endogenous PAX2 binds to the WNT5A
promoter in vivo, we performed ChIP analysis using HEK293 cells,
and an antibody, which conditions for specific binding to endoge-
nous PAX2, were recently optimized. Western blot analysis, using
HEK293 cells, protein extracts showed a specific band of an expected
size of ∼50 kDa, consistent with the molecular weight of PAX2
(Figure 1A). As shown in Figure 1B, a ∼300-bp fragment located up-
stream of WNT5A containing the putative PAX2 binding site was
amplified from PAX2 immunoprecipitates, indicating that endog-
enous PAX2 binds to the putative WNT5A regulatory region. Ad-
ditionally, amplification of the ∼300-bp fragment using the ChIP
product as template confirms the specificity of the NACE-enriched
fragment, corresponding to a regulatory element mapped ∼82 kb up-
stream of the WNT5A gene.
Transactivation Assays
To prove whether the NACE- and ChIP-derived ∼300-bp WNT5A
upstream fragment possessed a PAX2-responsive element, a transac-
tivation assay was performed. Monitoring luciferase activity revealed
that PAX2 significantly enhanced the expression from all WNT5A up-
stream element luciferase reporters, A, B, and AB (Figure 3). PAX2-
enhanced luciferase expression was greatest when cotransfected with
fragment A, whereas AB fragment expression was similar to the
P2BS control. The pGl3 empty vector was used as a negative control.
Table 3. Recapitulation of NACE-Generated Regulatory Elements Presumably Interacting with PAX2.
No. and Gene Symbol Locus Category No. and Gene Symbol Locus Category
01. ABLIM3 5q33.1 Adaptor 33. BIRC6 2p22.21 Protooncogene
02. CIB1 15q25.3-q26 Adhesion 34. HRB2 12q21.1 Protooncogene
03. CD4 12p13.31 Antigen 35. EIF2C4 1p34.3 Protooncogene
04. VRK2 2p16-p15 Enzyme 36. NOT4 7q33 Transcription factors
05. MAP2K5 15q22.2-31 Enzyme 37. RNF39 6P21.3 Transcription factors
06. GUCY1B2 13q14.2-14.3 Enzyme 38. SOX11 2P25.3 Transcription factors
07. DPP10 2q14.1 Enzyme 39. ZNF141 4p16.3 Transcription factors
08. ? Chromosome #9 Novel/hypothetical 40. BTG4 11q23.2-3 Transcription factors
09. ? 1q41 Novel/hypothetical 41. N6AM1 21q22.1 Transcription factors
10. ? XP11.22 Novel/hypothetical 42. GTF2B1 1p22.1-3 Transcription factors
11. ? Chromosome #17 Novel/hypothetical 43. ARHGAP8 22q13.31 Transcription factors
12. ? 9p24.1 Novel/hypothetical 44. WT1 and WIT1 11p13 Transcription factors
13. ? Chromosome #20 Novel/hypothetical 45. TCF4 18q21.1 Transcription factors
14. ? Chromosome #12 Novel/hypothetical 46. MAFK 7p22 Transcription factors
15. ? Chromosome #22 Novel/hypothetical 47. ELL2 5q15 RNA Associated
16. ? 1p32.1 Novel/hypothetical 48. NXT1 20p12 RNA Associated
17. ? Chromosome #7 Novel/hypothetical 49. SRRM2 16P13.3 RNA Associated
18. ? Chromosome #1 Novel/hypothetical 50. HTR1E 6q14-15 Signaling/receptor
19. ? Chromosome #4 Novel/hypothetical 51. MAPKAP1 9q34.11-12 Signaling/receptor
20. ? 18q21.1 Novel/hypothetical 52. DCAMKL1 9q34.11-12 Signaling/receptor
21. ? Chromosome #2 Novel/hypothetical 53. DLG2 11q Signaling/receptor
22. ? 11q14.1 Novel/hypothetical 54. CCKAR 4p15.2 Signaling/receptor
23. ? 22q122.1 Novel/hypothetical 55. AKAP13 15q24-25 Signaling/receptor
24. ? 21q21 Novel/hypothetical 56. TNFSF4 1q24-25 Signaling/receptor
25. ? 15q23 Novel/hypothetical 57. GEF6 Chromosome X Signaling/receptor
26. ? 3q26.31 Novel/hypothetical 58. PTPRM 18P11.2 Signaling/receptor
27. ? Chromosome #4 Novel/hypothetical 59. HARP Chromosome #16 Signaling/receptor
28. ? Chromosome #7 Novel/hypothetical 60. TNFRSF9 1p36 Signaling/receptor
29. ? Chromosome #9 Novel/hypothetical 61. ACTRT1 X26.1 Structural protein
30. ? 16q21-22.1 Novel/hypothetical 62. SH120 1P36.13 Structural protein
31. WNT5A 3p21.1 Protooncogene 63. ABLIM3 5q33.1 Structural protein
32. SEMA3E 7q21.11 Protooncogene 64. FAM36A 1q44 ?
Figure 2. Validation of NACE specificity. A representative example
of PCR amplification using NACE product as template and primers
designed to amplify the 5′upstream region of WNT5A and SOX11
genes. Both WNT5A and SOX11 were confirmed to be specifically
present in the PAX2 NACE product. Bands of the expected sizes
were obtained (arrows) specifically in PAX2-transfected samples
enriched by NACE. Material enriched from HEK293 cells trans-
fectd by an empty vector was used as a control along with water
and Ni2+ agarose beads (mocks).
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Electrophoretic Mobility Shift Assays
Based on data obtained with the transactivation assays, fragment A
was suspected to contain the binding site of PAX2. Six overlapping
biotin-labeled oligonucleotides (α, β, γ, δ, ɛ, and ζ), covering fragment
A as well as the PAX2 binding site P2BS, were synthesized (Table 2). A
protein extract from HEK293 cells was incubated with each oligo, and
reactions were resolved on a 10% polyacrylamide gel. In addition to that
observed with the P2BS oligo, a clear shift was obtained only with the
gamma-oligo (γ) (Figure 4A) indicating that the binding site is likely
located within this 30-bp sequence. The synthesis of an oligo gamma′
(γ′) where pyrimidines were replaced by purines and purines by pyrimi-
dines eliminated the observed shift (Figure 4A).
Figure 3. Transactivation assays of theWNT5A 5′-upstream region. The ∼300-bp NACE-enriched fragment (AB) and subfragments A and
B were cloned into the pGL-3 CMV luciferase vector. The three vectors were cotransfected with pcDNA-4/His/Max-PAX2 expression
vector and pRL-CMV internal control plasmid into HEK293 cells. Dual-luciferase activity ratios were calculated relative to express-tagged
PAX2 activation of P2BS, the PAX2 binding site reporter. Error bars, SEM.
Figure 4. PAX2 binding to sequences in theWNT5A 5′-upstream region. Electrophoretic mobility shift assay to assess the direct binding
of PAX2 to potential sequences including a synthetic control binding site (P2BS), the PAX2 binding site from the PAX2 5′-upstream
region (gamma-γ), and the same sequence altered by changing purines to pyrimidines and vice versa (gamma′-γ′). (▸) Arrowheads in-
dicate shifts caused by proteins-probes complex formation (A). An anti-Pax2 antibody was added to the complex formed between pro-
tein extracts and biotin-labeled gamma oligos to validate the specificity of the binding. A supershift migrating at higher molecular weight
was observed (B).
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To validate the specificity of the binding, we optimized conditions
for a supershift assay using a specific antibody to Pax2 protein. A
detectable label migrating at higher apparent molecular weight was
observed as a result of the anti-Pax2 antibody binding with the biotin-
labeled probes/protein extracts’ heterocomplexes (Figure 4B).
In Vitro siRNA-Mediated Silencing of PAX2 and WNT5A
To knock down PAX2 and WNT5A genes, we used siRNA formu-
lations commercialized by Qiagen and optimized to efficiently shut
down the expression of PAX2 and WNT5A. WiT49 cells were trans-
fected by either PAX2-siRNA1/PAX2-siRNA2 or WNT5A-siRNA2/
WN5A-siRNA6 sets. Cotransfection with both sets (PAX2-siRNA1
and PAX2-siRNA2 or WNT5A-siRNA2 and WN5A-siRNA6) was
highly toxic to the cells. An siRNA with no specific binding to hu-
man, mouse, and rat (sequence not revealed by the company) was
used as a negative control (Figure 5A). siRNA-treated samples were
subjected to Western analysis using antibodies directed against Pax2,
Wnt5a, and β-actin as loading controls. All the four siRNA signifi-
cantly contributed to a successful knock down of PAX2 and WNT5A
expression (Figure 5, B and C ). For PAX2 knock down, siRNA2
looks slightly more efficient than siRNA1 (Figure 5B), whereas for
WNT5A gene, siRNA2 seems more effectual than siRNA6 (Figure 5C).
β-Actin monitoring of the treated samples showed that the observed
knock down was not caused by an eventual loss of the material but by
siRNA treatment (Figure 5, B and C).
Mutation Screenings of WNT5A in WT Patients
The four exons covering the entire coding sequence of WNT5A
were amplified separately using primers listed in Table 1 and were
subjected to mutation analysis using DHPLC. None of the 99 WT
samples displayed a chromatogram with abnormal pattern when com-
pared to their control DNA samples, providing no evidence for exon-
specific mutations in WNT5A in WTs.
Quantitative Reverse Transcription–Polymerase
Chain Reaction
To assess the expression profile of WNT5A in WT samples, we per-
formed quantitative reverse transcription–polymerase chain reaction
Figure 5. siRNA-based knock down of PAX2 and WNT5A genes. Two locations within PAX2 and WNT5A genes were specifically tar-
geted to knock down their expression using commercialized siRNA (Qiagen). A nonspecific siRNA was used as a negative control where
protein expression is not altered in treated samples compared to nontreated samples (A). It is noteworthy that WNT5A expression is
weak when compared to the PAX2 expression in the WiT49 WT cell line. Both PAX2-siRNA1 and PAX2-siRNA2 were efficient to reduce
drastically PAX2 expression (B), whereas WNT5A expression was clearly detectable in the same samples (D). Culture medium where
WiT49 cells were propagated and treated with WNT5A-siRNA2 and WNT5A-siRNA6 was concentrated and subjected to Western blot
analysis using an anti-Wnt5A antibody. Like PAX2-siRNA, both WNT5A-siRNA2 and WNT5A-siRNA6 reduced the WNT5A expression (C).
The presence of PAX2 expression was detected in these WNT5A knocked down samples (E).
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(RT-PCR) using the TaqMan Gene Expression Assay from Applied
Biosystems on RNA isolated form favorable-histology WT samples.
Of the 38 cases tested, 25 showed significantly less expression of
WNT5A compared to the human fetal kidney control (Figure 6 and
Table 4). Exceptionally, one sample highly overexpressed WNT5A
relative to fetal kidney, whereas the expression levels in the remaining
12 cases were not significantly different from fetal kidney.
We subsequently examined the relationship between WNT5A ex-
pression and tumor histology. Samples were categorized in WNT5A
expression as either aberrant or normal and compared to histologic
classification based on predominant histologic finding; that is, blas-
temal, epithelial, or stromal as determined on central pathology re-
view on Children’s Oncology Group study AREN03B2 (Table 4).
Fifteen samples showed predominant blastemal histology, two sam-
ples showed predominant epithelial histology, and the remainder
showed predominantly stromal histology. Using the McNemar exact
test for nonparametric data, a significant correlation between WNT5A
underexpression and predominant blastemal histology was observed
(P = .000122, n = 14/38).
Discussion
We used the HEK293 cell line to identify target genes regulated by
PAX2, a transcription factor known for its role in kidney develop-
ment [33]. Our preliminary experiments revealed that this cell line
expresses PAX2, making it an appropriate model to isolate and test
the predicted target regulatory elements. In contrast to most cancers
where both animal models and cell lines are available, the study of
WT still suffers from the lack of good cell line models. The few WT
lines that have been reported, including WiT49 and HWFT, usually
harbor a p53 mutation, characteristic of the anaplastic variant of WT
and likely not representative of the much more common favorable-
histology WT (95% of WTs are favorable histology), which rarely
includes mutation of the p53 gene [34,35]. We chose HEK293 cells
as a very well characterized line, which is easily used for transfection/
transactivation assays, especially for its human embryonic kidney ori-
gin. However, findings generated by using this model remain specu-
lative because a good cell line representing favorable-histology WTs
have not yet been established.
BLAST sequence analysis of the PAX2 NACE-derived sequences
revealed responsive elements from a variety of genes including adhe-
sion proteins, proto-oncogenes, transcription factors, and some novel
genes (Table 3). Approximately 54% of the clones (76/140) were ei-
ther repetitive sequences or could not be sequenced and were ex-
cluded from further analysis.
Among the potential PAX2 targets obtained using the NACE and
ChIP techniques, a ∼300-bp WNT5A 5′-upstream element was par-
ticularly interesting. WNT genes are expressed in a variety of human
tissues, including bladder and fetal kidney, and, therefore, play a
major role in kidney development [33] and is implicated in cancer
[36]. The NACE-enriched fragment, localized ∼82 kb upstream of
the WNT5A gene, is conserved between human and mice and repre-
Figure 6. Quantitative RT-PCR to assess the expression levels of WNT5A in WT samples of favorable-histology. Gene expression assay
(Applied Biosystems) was performed on 38 WT samples. Human fetal kidney was included as a control to which all data were normal-
ized. Error bars, relative SE.
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sents one of the upstream noncoding putative regulatory regions
(Figure 7). Likewise, the identified ∼300 bp lies within an area be-
longing to other genes located in the vicinity, notably within the last
intron of ERC2 gene, upstream the WNT5A. Owing to its central
position in several developmental pathways and its involvement in
the control of different steps in certain organs’ formation including
the kidney [13], PAX2 can adopt polyvalent functions and has the
capacity to interact simultaneously with different entities.
The results of our transactivation experiments demonstrated that
the WNT5A upstream element was sufficient to provide PAX2-
dependent activation of gene expression and led to the identifica-
tion of an authentic PAX2 responsive element within the 155-bp
subfragment of the WNT5A 5′-upstream element (Figure 3). The
fragment contains a DNA sequence to which PAX2 binds specifically
as shown by EMSA and confirmed by the supershift assay (Fig-
ure 4B). Moreover, mutations of (γ), the fragment harboring the pu-
tative PAX2 binding site, resulted in a complete removal of the
observed shift (Figure 4A). Surprisingly, the subfragment A displayed
the highest luciferase expression activity compared to the positive
control (PAX2BS) and particularly to the total fragment AB of
∼300 bp (Figure 3). This discrepancy might be caused by the pres-
ence of an inhibitory element in fragment AB, which is not present
in the smaller fragment A (Figure 3).
Because we found that WNT5A is a direct target of the PAX2
gene, which itself interacts reciprocally with WT1, and because
WT1 is known to be involved in approximately 15% of sporadic
WTs [37], we tested whether mutations of WNT5A could be de-
tected in WTs. The analysis of a panel of 99 WT samples revealed
no disease-associated mutations, however, indicating that mutation
of WNT5A itself is unlikely to be a significant cause of WT.
Interestingly, however, the expression levels ofWNT5A in favorable-
histologyWTs, assessed by quantitative RT-PCR, showed that approx-
imately two-thirds of the cases displayed significantly less WNT5A
expression than human fetal kidney control (Figure 6). Furthermore,
there seemed to be a significant correlation between low WNT5A
expression levels and categorization of the tumors as having pre-
dominantly blastemal histology.
The development of the metanephric kidney is at least a two-step
process in which the undifferentiated metanephric mesenchyme is
rescued from apoptosis by the developing ureteric bud and subse-
quently triggered into a mesenchymal-epithelial conversion to form
the mature nephron [38]. Tissue that has been rescued from the
apoptotic fate, but is to receive the second transition signal, is often
termed the metanephric blastema. In general, the first transition occurs
in cells proximal to the invading ureteric bud, whereas subsequent
transitions are observed after primary and secondary branchings have
occurred. Thus, the topography of the developing kidney is reflective
of its chronological maturity, with the “earliest” developmental stages
occurring near the outer edges around the buds of the invading ureters
and the “mature” tissue appearing at the core.
Some WTs are characterized by a histologic pattern where prolifer-
ation of undifferentiated metanephric blastemal cells is predominant
[39] suggesting that errors in the second stage of nephrogenesis may
be involved in Wilms tumorigenesis. In this context, the correlation
between the underexpression ofWNT5A and predominantly blastemal
tumor histology could represent a cause for the absence of a secondary
transition (i.e., mesenchymal-epithelial transition). However, given
that WNTsignaling pathway genes are affected by the promoter meth-
ylation status [40], WNT5A underexpression in WT samples could
be the result of its promoter hypermethylation that hampers the nor-
mal transcription of the gene.
As a signal transducer, WNT5A might be suited for a key role in
the complex cellular cross-talk between the developing ureter and the
developing epithelia. Interestingly, up-regulation of WNT5A has pre-
viously been shown to suppress tubule branching during lung devel-
opment [41]. WNT5A has also been implicated in regulating the
mesenchymal-epithelial transition in uterine tissue [42].
In addition to its role in the regulation of branching morphogenesis
[43,44], PAX2 is also up-regulated during early kidney development
and repressed in mature renal tissue [15,45]. Furthermore, PAX2 is con-
stitutively expressed in a variety of renal tumors including WT [45].
The PAX2 knock down using specific siRNA and the WiT5AWT line
showed a detectable level of WNT5A protein expression in samples
treated with PAX2-siRNA1 and PAX2-siRNA2 (Figure 5, B and D).
WNT5A expression increased slightly in both samples treated with
PAX2-siRNA1 and PAX2-siRNA2 compared with nontreated samples
(Figure 5, A, B, andD). Likewise, a detectable level of PAX2 protein ex-
pression was detected in samples that had undergoneWNT5A-siRNA2
and WNT5A-siRNA6 transfection (Figure 5, C and E). Based on this
in vitro siRNA data, it is likely that when PAX2 is highly expressed (i.e.,
in WT), the WNT5A is down-regulated (Figure 5A) and vice versa, al-
though an in vivo studywould bemore suitable to confirm this hypothesis.
Table 4. Expression Analysis and Histology Classification for the 38-Sample Experimental Set.
Sample ID No. ΔC t σ Test
Statistic
P Significance
[α < 0.05]
Histology
Classification
Control HFK cDNA 10.27 0.86 0 1 No –
1 50106-1 15.30 0.69 7.919 .02 Yes Epithelial
2 50031-1 8.09 0.29 4.155 .05 Yes* Epithelial
3 50015-1 14.23 0.74 6.047 .03 Yes Blastemal
4 50090-1 11.33 0.38 1.954 .19 No Stromal
5 50130-1 16.94 1.24 7.657 .02 Yes Blastemal
6 50082-1 9.44 0.29 1.582 .25 No Stromal
7 50269-1 14.30 0.40 7.369 .02 Yes Stromal
8 50227-1 14.93 1.17 5.565 .03 Yes Blastemal
9 50295-1 17.01 2.12 5.106 .04 Yes Stromal
10 50369-1 11.98 0.61 2.825 .11 No Stromal
11 50415-1 13.42 0.50 5.505 .03 Yes Stromal
12 50440-1 13.81 1.21 4.147 .05 Yes Stromal
13 50441-1 13.99 0.28 7.143 .02 Yes Stromal
14 50517-1 10.13 0.29 0.266 .82 No Stromal
15 50838-1 14.27 0.71 6.223 .02 Yes Blastemal
16 50627-1 9.36 0.20 1.776 .22 No Stromal
17 51168-1 10.89 0.15 1.25 .34 No Stromal
18 50795-1 13.89 1.44 3.742 .06 No Blastemal
19 50741-1 15.24 0.92 6.842 .02 Yes Blastemal
20 50748-1 13.73 0.63 5.648 .03 Yes Blastemal
21 50644-1 15.20 0.33 9.291 .01 Yes Blastemal
22 50738-1 12.38 0.14 4.21 .05 Yes Blastemal
23 50848-1 12.69 0.58 4.035 .06 No Blastemal
24 50437-1 17.07 0.13 13.57 .01 Yes Blastemal
25 50615-1 15.92 0.71 8.768 .01 Yes Blastemal
26 50569-1 10.30 0.59 0.048 .97 No Stromal
27 50159-1 11.36 2.17 0.813 .5 No Stromal
28 50215-1 12.85 0.10 5.183 .04 Yes Stromal
29 50164-1 12.78 0.11 5.039 .04 Yes Stromal
30 50218-1 17.60 0.04 14.789 0 Yes Blastemal
31 50118-1 9.24 0.42 1.854 .2 No Stromal
32 50098-1 14.34 0.26 7.871 .02 Yes Stromal
33 50151-1 17.99 0.44 13.88 .01 Yes Stromal
34 50017-1 12.71 0.37 4.533 .05 Yes Stromal
35 50095-1 14.04 0.16 7.494 .02 Yes Blastemal
36 50009-1 11.88 0.56 2.733 .11 No Stromal
37 50120-1 17.83 0.09 15.176 0 Yes Stromal
38 50073-1 14.28 0.62 6.547 .02 Yes Stromal
*This sample showed significant over expression (Figure 1).
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Reconciling these data with the expression analysis in Figure 6, it
is tempting to speculate that PAX2 and WNT5A share an inhibitory-
like cross-relationship. PAX2 tends to be overexpressed in Wilms
tumors, whereas WNT5A tends to be underexpressed, and given that
we now demonstrate that PAX2 plays a specific regulatory role in-
volving a cis-region of the WNT5A gene, an inhibitory relationship
is entirely plausible.
During early renal development, up-regulated PAX2 is suppressed by
WT1 after the completion of the first transitional stage [45], in more
mature tissue, a dichotomy that is crucial to proper nephrogenesis
[46]. PAX2 inhibition of WNT5A would then be relieved, promoting
the second transitional step. When PAX2 is constitutively up-regulated,
as it is in certain cases of WT, this second stage would not occur as re-
flected in the tumor histology (i.e., predominately blastemal).
A very recently discovered tumor suppressor gene WTX, operating
through β-catenin, was shown to suppress the canonical WNT sig-
naling pathway by enhancing β-catenin degradation [47]. Likewise,
WNT5A was also shown to antagonize canonical Wnt/β-catenin sig-
naling pathway [48] and regulate cell proliferation [49]. Given that
both WTX and WNT5A genes block the Wnt/β-catenin signaling
pathway, it is therefore likely that both genes operate through the
same chain of command line [47,48]. This is the first report indicat-
ing a direct relationship between PAX2 and WNT5A in the human
embryonic kidney cells (HEK293) and indicating the importance of
PAX2 in the regulation of this transcription factor and member of the
WNT pathway. Further study is necessary to identify other interme-
diary molecules involved in these pathways and to determine whether
the PAX2 and WNT5A are truly involved in WT pathogenesis.
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